ImmunityBio
IBRX
IBRX
126 hedge funds and large institutions have $196M invested in ImmunityBio in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 50 increasing their positions, 26 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
19% less call options, than puts
Call options by funds: $3.06M | Put options by funds: $3.79M
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
Holders
126
Holding in Top 10
1
Calls
$3.06M
Puts
$3.79M
Top Buyers
| 1 | +$23.8M | |
| 2 | +$2.77M | |
| 3 | +$1.99M | |
| 4 |
Citigroup
New York
|
+$1.78M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.73M |
Top Sellers
| 1 | -$3.88M | |
| 2 | -$1.67M | |
| 3 | -$1.49M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.14M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$505K |